163 related articles for article (PubMed ID: 27461240)
21. Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection.
Brumbaugh AR; Smith SN; Mobley HL
Infect Immun; 2013 Sep; 81(9):3309-16. PubMed ID: 23798537
[TBL] [Abstract][Full Text] [Related]
22. Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.
Poggio TV; La Torre JL; Scodeller EA
Can J Microbiol; 2006 Nov; 52(11):1093-102. PubMed ID: 17215901
[TBL] [Abstract][Full Text] [Related]
23. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
24. In silico design and in vivo evaluation of two multi-epitope vaccines containing build-in adjuvant with chitosan nanoparticles against uropathogenic Escherichia coli.
Rezaei M; Esmaeili F; Reza Asadi Karam M; Ehsani P; Abbasnezhad Farsangi Z; Bouzari S
Int Immunopharmacol; 2023 Apr; 117():109999. PubMed ID: 37012877
[TBL] [Abstract][Full Text] [Related]
25. Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile.
Bruxelle JF; Mizrahi A; Hoÿs S; Collignon A; Janoir C; Péchiné S
PLoS One; 2017; 12(11):e0187212. PubMed ID: 29176760
[TBL] [Abstract][Full Text] [Related]
26. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
Akhiani AA; Stensson A; Schön K; Lycke N
Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
[TBL] [Abstract][Full Text] [Related]
27. [Urinary tract infections, immunity, and vaccination].
Luna-Pineda VM; Ochoa S; Cruz-Córdova A; Cázares-Domínguez V; Vélez-González F; Hernández-Castro R; Xicohtencatl-Cortes J
Bol Med Hosp Infant Mex; 2018; 75(2):67-78. PubMed ID: 29658949
[TBL] [Abstract][Full Text] [Related]
28. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice.
Xue G; Yu L; Li S; Shen X
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):202-10. PubMed ID: 19912341
[TBL] [Abstract][Full Text] [Related]
29. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice.
Sasaki K; Kato M; Takahashi T; Ochi S; Ichinose Y; Shiraki K; Asano Y; Iwanaga M; Tsuji T
J Med Virol; 2003 Jun; 70(2):329-35. PubMed ID: 12696126
[TBL] [Abstract][Full Text] [Related]
30. In silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic Escherichia coli.
Hasanzadeh S; Habibi M; Shokrgozar MA; Ahangari Cohan R; Ahmadi K; Asadi Karam MR; Bouzari S
Sci Rep; 2020 Oct; 10(1):16258. PubMed ID: 33004862
[TBL] [Abstract][Full Text] [Related]
31. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
32. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
Strindelius L; Filler M; Sjöholm I
Vaccine; 2004 Sep; 22(27-28):3797-808. PubMed ID: 15315861
[TBL] [Abstract][Full Text] [Related]
33. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract.
Lane MC; Alteri CJ; Smith SN; Mobley HL
Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16669-74. PubMed ID: 17925449
[TBL] [Abstract][Full Text] [Related]
34. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.
Asadi Karam MR; Habibi M; Bouzari S
Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763
[TBL] [Abstract][Full Text] [Related]
35. Physical Extraction and Fast Protein Liquid Chromatography for Purifying Flagella Filament From Uropathogenic
Acharya D; Sullivan MJ; Duell BL; Eveno T; Schembri MA; Ulett GC
Front Cell Infect Microbiol; 2019; 9():118. PubMed ID: 31069177
[TBL] [Abstract][Full Text] [Related]
36. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
Siadat-Pajouh M; Cai L
Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
[TBL] [Abstract][Full Text] [Related]
37. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
[TBL] [Abstract][Full Text] [Related]
38. [The adjuvant effect of chimeric flagellin fliC/esat].
Zhang H; Wen K; Huang JL; Hu MZ; Shen JS; Pan ZM; Jiao XA
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Apr; 27(4):377-81. PubMed ID: 21481310
[TBL] [Abstract][Full Text] [Related]
39. In Vivo Consumption of Cranberry Exerts ex Vivo Antiadhesive Activity against FimH-Dominated Uropathogenic Escherichia coli: A Combined in Vivo, ex Vivo, and in Vitro Study of an Extract from Vaccinium macrocarpon.
Rafsanjany N; Senker J; Brandt S; Dobrindt U; Hensel A
J Agric Food Chem; 2015 Oct; 63(40):8804-18. PubMed ID: 26330108
[TBL] [Abstract][Full Text] [Related]
40. Development of a Vaccine against Escherichia coli Urinary Tract Infections.
Mobley HL; Alteri CJ
Pathogens; 2015 Dec; 5(1):. PubMed ID: 26729174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
